Details of the Drug-Related molecule(s) Interaction Atlas

General Information of DTT (ID: TTEC2T3)

• DTT Name: Human immunodeficiency virus Envelope glycoprotein gp160 (HIV env) DTT Info
• Gene Name: HIV env

Molecule-Related Drug & Molecule List

5 Clinical Trial Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Ad35-GRIN/ENV	DMG82ZA	Human immunodeficiency virus infection	1C62	Phase 1	[1]
Ad5-ENVA-48	DMMBQV3	Human immunodeficiency virus-1 infection	1C62	Phase 1	[2]
MGD014	DMZN5QX	Human immunodeficiency virus-1 infection	1C62	Phase 1	[3]
PENNVAX-6	DM0BNLC	Human immunodeficiency virus infection	1C62	Phase 1	[4]
TBC-M4	DM9CDPO	Human immunodeficiency virus infection	1C62	Phase 1	[5]

1 Discontinued Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
GPG	DMYR7LO	Human immunodeficiency virus infection	1C62	Discontinued in Phase 1/2	[6]

References

• [1] A phase I double blind, placebo-controlled, randomized study of a multigenic HIV-1 adenovirus subtype 35 vector vaccine in healthy uninfected adults. PLoS One. 2012;7(8):e41936.
• [2] ClinicalTrials.gov (NCT00695877) Safety and Immune Response to a Recombinant Adenovirus HIV-1 Vaccine in Healthy Adults. U.S. National Institutes of Health.
• [3] Clinical pipeline report, company report or official report of MacroGenics.
• [4] Company report (Inovio)
• [5] A Phase 1 study to evaluate the safety and immunogenicity of a recombinant HIV type 1 subtype C-modified vaccinia Ankara virus vaccine candidate in Indian volunteers. AIDS Res Hum Retroviruses. 2009 Nov;25(11):1107-16.
• [6] GPG-NH2 acts via the metabolite alphaHGA to target HIV-1 Env to the ER-associated protein degradation pathway. Retrovirology 2010, 7:20.